Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1

被引:140
作者
Fader, Lee D. [1 ]
Malenfant, Eric [1 ]
Parisien, Mathieu [1 ]
Carson, Rebekah [1 ]
Bilodeau, Francois [1 ]
Landry, Serge [1 ]
Pesant, Marc [1 ]
Brochu, Christian [1 ]
Morin, Sebastien [1 ]
Chabot, Catherine [1 ]
Halmos, Ted [1 ]
Bousquet, Yves [1 ]
Bailey, Murray D. [1 ]
Kawai, Stephen H. [1 ]
Coulombe, Rene [1 ]
LaPlante, Steven [1 ]
Jakalian, Araz [1 ]
Bhardwaj, Punit K. [1 ]
Wernic, Dominik [1 ]
Schroeder, Patricia [1 ]
Amad, Ma'an [1 ]
Edwards, Paul [1 ]
Garneau, Michel [1 ]
Duan, Jianmin [1 ]
Cordingley, Michael [1 ]
Bethell, Richard [1 ]
Mason, Stephen W. [1 ]
Boes, Michael [1 ]
Bonneau, Pierre [1 ]
Poupart, Marc-Andre [1 ]
Faucher, Anne-Marie [1 ]
Simoneau, Bruno [1 ]
Fenwick, Craig [1 ]
Yoakim, Christiane [1 ]
Tsantrizos, Youla [1 ]
机构
[1] Boehringer Ingelheim Canada Ltd, Res & Dev, Laval, PQ H7S 2G5, Canada
关键词
HIV Integrase; allosteric inhibitor; LTR DNA 3 '-processing; NCINI; SMALL-MOLECULE INHIBITORS; BINDING-SITE; IDENTIFICATION; LEDGF/P75; MECHANISM; ERA;
D O I
10.1021/ml500002n
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
An assay recapitulating the 3' processing activity of HIV-1 integrase (IN) was used to screen the Boehringer Ingelheim compound collection. Hit-to-lead and lead optimization beginning with compound 1 established the importance of the C3 and C4 substituent to antiviral potency against viruses with different aa124/aa125 variants of IN. The importance of the C7 position on the serum shifted potency was established. Introduction of a quinoline substituent at the C4 position provided a balance of potency and metabolic stability. Combination of these findings ultimately led to the discovery of compound 26 (BI 224436), the first NCINI to advance into a phase Ia clinical trial.
引用
收藏
页码:422 / 427
页数:6
相关论文
共 26 条
[1]   Advances in antiretroviral therapy [J].
Arribas, Jose R. ;
Eron, Joseph .
CURRENT OPINION IN HIV AND AIDS, 2013, 8 (04) :341-349
[2]   Non-Catalytic Site HIV-1 Integrase Inhibitors Disrupt Core Maturation and Induce a Reverse Transcription Block in Target Cells [J].
Balakrishnan, Mini ;
Yant, Stephen R. ;
Luong Tsai ;
O'Sullivan, Christopher ;
Bam, Rujuta A. ;
Tsai, Angela ;
Niedziela-Majka, Anita ;
Stray, Kirsten M. ;
Sakowicz, Roman ;
Cihlar, Tomas .
PLOS ONE, 2013, 8 (09)
[3]  
Calin R, 2013, CLIN PRACT, V10, P427
[4]   Adverse effects of antiretroviral therapy [J].
Carr, A ;
Cooper, DA .
LANCET, 2000, 356 (9239) :1423-1430
[5]   Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75 [J].
Cherepanov, P ;
Ambrosio, ALB ;
Rahman, S ;
Ellenberger, T ;
Engelman, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (48) :17308-17313
[6]   Small-Molecule Inhibitors of the LEDGF/p75 Binding Site of Integrase Block HIV Replication and Modulate Integrase Multimerization [J].
Christ, Frauke ;
Shaw, Stephen ;
Demeulemeester, Jonas ;
Desimmie, Belete A. ;
Marchand, Arnaud ;
Butler, Scott ;
Smets, Wim ;
Chaltin, Patrick ;
Westby, Mike ;
Debyser, Zeger ;
Pickford, Chris .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (08) :4365-4374
[7]   Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication [J].
Christ, Frauke ;
Voet, Arnout ;
Marchand, Arnaud ;
Nicolet, Stefan ;
Desimmie, Belete A. ;
Marchand, Damien ;
Bardiot, Dorothee ;
Van der Veken, Nam Joo ;
Van Remoortel, Barbara ;
Strelkov, Sergei V. ;
De Maeyer, Marc ;
Chaltin, Patrick ;
Debyser, Zeger .
NATURE CHEMICAL BIOLOGY, 2010, 6 (06) :442-448
[8]  
Clavel F, 2004, NEW ENGL J MED, V350, P1023, DOI 10.1056/NEJM2ra025195
[9]   The molecular biology of HIV integrase [J].
Craigie, Robert .
FUTURE VIROLOGY, 2012, 7 (07) :679-686
[10]   CRYSTAL-STRUCTURE OF THE CATALYTIC DOMAIN OF HIV-1 INTEGRASE - SIMILARITY TO OTHER POLYNUCLEOTIDYL TRANSFERASES [J].
DYDA, F ;
HICKMAN, AB ;
JENKINS, TM ;
ENGELMAN, A ;
CRAIGIE, R ;
DAVIES, DR .
SCIENCE, 1994, 266 (5193) :1981-1986